Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics Inc (NQ: FULC )

3.250 +0.280 (+9.43%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fulcrum Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
What 6 Analyst Ratings Have To Say About Fulcrum Therapeutics
Via Benzinga
Expert Ratings for Fulcrum Therapeutics
Via Benzinga
Why Fulcrum Therapeutics Shares Are Falling
Fulcrum Therapeutics Inc (NASDAQ: FULC) shares are trading lower by 6.43% to $13.09 Wednesday morning after the company announced pricing of an upsized public offering of common stock. 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fulcrum Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Via Benzinga
uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday
UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market... 
Via Benzinga
Dow Dips 350 Points; S&P 500 Down Over 1%
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 300 points on Friday. The Dow traded down 1.07% to 32,798.91 while the NASDAQ fell 1.90% to 11,370.53. The S&P 500... 
Via Benzinga
Stocks Extend Slump, Head For Weekly Losses
Stocks are extending their premarket losses, with the Dow Jones Industrial Average down 409 points. 
Via Talk Markets
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday. 
Via Benzinga
Nasdaq Tumbles 2%; Timber Pharmaceuticals Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 450 points on Friday. The Dow traded down 1.39% to 32,692.94 while the NASDAQ fell 2.14% to 11,342.36. The S&P 500 also... 
Via Benzinga
FDA Slams Break On Fulcrum Therapeutics' Sickle Cell Disease Study, Shares Plummet
Via Benzinga
Fulcrum Therapeutics (FULC) Stock Plummets 55% on Clinical Hold News
FULC stock is falling fast today due to a regulatory issue, but Fulcrum Therapeutics remains committed to combating sickle cell disease. 
Via InvestorPlace
US Stocks Open Lower; Dow Drops 1%
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Friday. Following the market opening Friday, the Dow traded down 1.05% to 32,807.33 while the NASDAQ fell 1.52% to... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
The Week In Charts - Becoming A Successful Trader
Dave discusses various topics, including intra-day trading and trading opening gap reversals, the current stock market conditions, and his two cents on your favorite stock picks. 
Via Talk Markets
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
$3.4 Million Bet On CrowdStrike Holdings? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed sharply higher on Friday, there were a few notable insider trades. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.